Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bevra H Hahn

Showing results (1-10 of 100) with videos related to

Pageof 10
Sort By:
Annals of the Rheumatic Diseases|February 23, 2011
Targeted therapies in systemic lupus erythematosus: successes, failures and futureBevra H Hahn
Arthritis and Rheumatism|February 5, 2010
Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis?Bevra H Hahn
Current Opinion in Immunology|December 18, 2007
Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the associationMaureen McMahon, Bevra H Hahn
Best Practice & Research. Clinical Rheumatology|December 11, 2007
Systemic lupus erythematosus: modern strategies for management: a moving targetJennifer K King, Bevra H Hahn
Nature Clinical Practice. Rheumatology|January 5, 2007
Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone lossBevra H Hahn, Theodore J Hahn
The American Journal of Medicine|September 5, 2002
Improving joint disease in patients with rheumatoid arthritis: is this enough to treat the accompanying dyslipidemias?Bevra H Hahn, Jennifer Grossman, Kenneth Kalunian
Expert Review of Clinical Immunology|March 24, 2011
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic interventionMaureen McMahon, Bevra H Hahn, Brian J Skaggs
Expert Opinion on Biological Therapy|February 25, 2009
Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosusNoriko Iikuni, Bevra H Hahn, Antonio La Cava
Journal of Immunology (Baltimore, Md. : 1950)|May 3, 2013
Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like diseaseMaida Wong, Antonio La Cava, Bevra H Hahn
Nature Reviews. Rheumatology|February 15, 2012
Accelerated atherosclerosis in patients with SLE--mechanisms and managementBrian J Skaggs, Bevra H Hahn, Maureen McMahon
Pageof 10

Showing results (1-10 of 100) with videos related to

Sort By:
Pageof 10
Annals of the Rheumatic Diseases|February 23, 2011
Targeted therapies in systemic lupus erythematosus: successes, failures and futureBevra H Hahn
Arthritis and Rheumatism|February 5, 2010
Should antibodies to high-density lipoprotein cholesterol and its components be measured in all systemic lupus erythematosus patients to predict risk of atherosclerosis?Bevra H Hahn
Current Opinion in Immunology|December 18, 2007
Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the associationMaureen McMahon, Bevra H Hahn
Best Practice & Research. Clinical Rheumatology|December 11, 2007
Systemic lupus erythematosus: modern strategies for management: a moving targetJennifer K King, Bevra H Hahn
Nature Clinical Practice. Rheumatology|January 5, 2007
Alendronate versus alfacalcidol in the prevention of glucocorticoid-induced bone lossBevra H Hahn, Theodore J Hahn
The American Journal of Medicine|September 5, 2002
Improving joint disease in patients with rheumatoid arthritis: is this enough to treat the accompanying dyslipidemias?Bevra H Hahn, Jennifer Grossman, Kenneth Kalunian
Expert Review of Clinical Immunology|March 24, 2011
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic interventionMaureen McMahon, Bevra H Hahn, Brian J Skaggs
Expert Opinion on Biological Therapy|February 25, 2009
Potential for anti-DNA immunoglobulin peptide therapy in systemic lupus erythematosusNoriko Iikuni, Bevra H Hahn, Antonio La Cava
Journal of Immunology (Baltimore, Md. : 1950)|May 3, 2013
Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like diseaseMaida Wong, Antonio La Cava, Bevra H Hahn
Nature Reviews. Rheumatology|February 15, 2012
Accelerated atherosclerosis in patients with SLE--mechanisms and managementBrian J Skaggs, Bevra H Hahn, Maureen McMahon
Pageof 10